A medication that stops Alzheimer's in its tracks?

Share this article:

Baxter BioScience's Gammagard halted the progression of Alzheimer's disease for as long as three years in a 16-patient trial. Results were presented at the Alzheimer's Association's annual meeting in Vancouver. The findings offer a “tantalizing” glimpse of the drug's potential, said William Thies, the association's chief medical and scientific officer.

A definitive study of 390 patients will be completed this year and released in early 2013, said Norman Relkin, the lead researcher, and the director of the Memory Disorders Program and a neurologist at New York Presbyterian/Weill Cornell Medical Center.

Share this article:
close

Next Article in Products

More in Products

LeadingAge's CAST releases medication management tools

LeadingAge's Center for Aging Services Technologies release new tools last week to help long-term care providers identify the best medication management product.

Butler Mobility updates paint colors for platform lifts

Butler Mobility updates paint colors for platform lifts

Butler Mobility has widened the spectrum of paint color choices for its Incline Platform Lifts line.

NeuroMetrix releases pain management system

NeuroMetrix releases pain management system

NeuroMetrix Inc. has created the SENSUS™ Pain Management System, a wearable neurostimulation technology developed for chronic neuropathic pain, including painful diabetic neuropathy.